keyword
MENU ▼
Read by QxMD icon Read
search

Macular edema

keyword
https://www.readbyqxmd.com/read/28630791/corticosteroid-treatment-in-diabetic-macular-edema
#1
REVIEW
Burcu Nurözler Tabakcı, Nurten Ünlü
Diabetic macular edema is the most common cause of visual impairment in patients with diabetes mellitus. The pathogenesis of macular edema is complex and multifactorial. For many years, laser photocoagulation has been considered the standard therapy for the treatment of diabetic macular edema; however, few patients achieve significant improvements in visual acuity. Today the intravitreal administration of anti-inflammatory or anti-angiogenic agents together with the use of laser photocoagulation represents the standard of care for the treatment of this complication...
June 2017: Turkish Journal of Ophthalmology
https://www.readbyqxmd.com/read/28629694/interleukin-6-participation-in-pathology-of-ocular-diseases
#2
REVIEW
Forouhe Zahir-Jouzdani, Fatemeh Atyabi, Nazanin Mojtabavi
Interleukin-6 (IL-6) is a multifunctional cytokine that affects a variety of cells in the body such as osteoclasts, hepatocytes, endothelial cells, epithelial cells, white and red blood cells and etc. Elevated levels of IL-6 have been detected in many ocular diseases. Studies show that IL-6 has a major role in the pathology of glaucoma, CRVO, macular edema, ocular neovascularization, posterior capsule opacity formation, keratitis, dry eye disease, allergic eye disease, ocular autoimmune disease, corneal chemical burn, ocular inflammation and so on...
June 10, 2017: Pathophysiology: the Official Journal of the International Society for Pathophysiology
https://www.readbyqxmd.com/read/28629400/characteristics-of-syphilitic-uveitis-in-northern-china
#3
Xiaomin Zhang, Qian Du, Feifei Ma, Yinglong Lu, Meiyan Wang, Xiaorong Li
BACKGROUND: To describe the characteristics of patients with syphilitic uveitis in northern China. METHODS: A case series of 21 patients (33 eyes) diagnosed with syphilitic uveitis from 2011 to 2016 at a tertiary center in northern China was retrospectively analyzed. RESULTS: Twenty-one patients (33 eyes) were diagnosed as syphilitic uveitis. Posterior segment involvement was found in 32 eyes (97.0%). Vitreous haze, neuroretinitis, and posterior placoid chorioretinitis were mainly found in patients with a relatively short duration of the disease, while diffuse chorioretinitis, pseudoretinitis pigmentosa, cystoid macular edema, and epiretinal membrane were found in patients with relatively long duration of ocular involvement...
June 19, 2017: BMC Ophthalmology
https://www.readbyqxmd.com/read/28628490/comparison-of-efficacy-of-difluprednate-0-05-and-loteprednol-gel-0-5-after-cataract-surgery
#4
Bryan Abessi, Lauren Brooksby, Robert L Schultze
PURPOSE: To compare the outcomes and complications of topical difluprednate 0.05% and loteprednol gel 0.5% after routine cataract surgery. METHODS: Subjects received either difluprednate emulsion 0.05% (n=30 eyes) or loteprednol gel 0.5% (n=30 eyes) after routine cataract surgery. Topical steroid drops were initiated 3 days before cataract surgery and continued for 2 weeks postoperatively. Anterior chamber (AC) cell grade, corneal edema, corneal pachymetry, visual acuity, ocular surface quality (Oxford scale), and intraocular pressure (IOP) were evaluated at 1 day, 1 week, and 1 month postoperatively...
June 16, 2017: Eye & Contact Lens
https://www.readbyqxmd.com/read/28626824/atypical-chronic-central-serous-chorioretinopathy-with-cystoid-macular-edema-therapeutic-response-to-medical-and-laser-therapy
#5
Jiun L Do, Lisa C Olmos de Koo, Hossein Ameri
PURPOSE: To describe an atypical case of chronic central serous chorioretinopathy (CSCR). METHODS: A 58-year-old man with longstanding, bilateral visual impairment was self-referred for a second opinion. RESULTS: Findings by direct ophthalmoscopy, optical coherence tomography, fluorescein angiography, and fundus autofluorescence (FAF) were suggestive of atypical, chronic CSCR. Treatment with oral anti-mineralocorticoids resulted in moderate improvement, and photodynamic therapy (PDT) had minimal effect...
June 2017: Journal of Current Ophthalmology
https://www.readbyqxmd.com/read/28625129/triamcinolone-acetonide-suppresses-inflammation-and-facilitates-vascular-barrier-function-in-human-retinal-microvascular-endothelial-cells
#6
Shunsuke Imai, Tomohiro Otsuka, Akira Naito, Masamitsu Shimazawa, Hideaki Hara
BACKGROUND: Diabetic macular edema (DME) is resulted from the retinal microvascular leakage that accompanies the breakdown of blood-retinal barrier. Triamcinolone acetonide (TA) is a therapeutic agent for DME, but since the detailed mechanism of action of TA is not known, part of its action was examined. METHODS: In vitro model to enhance the permeability of human retinal microvascular endothelial cells (HRMECs) was constructed by using DME-related cytokines such as vascular endothelial growth factor (VEGF), tumor necrosis factor-α (TNF-α), and interleukin-1β (IL-1β)...
June 18, 2017: Current Neurovascular Research
https://www.readbyqxmd.com/read/28624313/eplerenone-a-new-treatment-for-an-old-problem-retinitis-pigmentosa-with-recalcitrant-macular-edema
#7
R Campos Polo, C Rubio Sánchez, D M García Guisado, M J Díaz Luque
CASE REPORT: The case involves a 35-year-old man, with a history of retinitis pigmentosa, who presented with a bilateral cystoid macular oedema associated with bilateral epiretinal membrane, which was resistant to treatment with oral acetazolamide and intravitreal bevacizumab. The treatment with oral eplerenone was able to improve the visual acuity and macular thickness of this patient. DISCUSSION: A variety of treatments have been proposed for the management of cystoid macular oedema, associated with retinitis pigmentosa, with variable results...
June 14, 2017: Archivos de la Sociedad Española de Oftalmología
https://www.readbyqxmd.com/read/28622321/identification-of-time-point-to-best-define-sub-optimal-response-following-intravitreal-ranibizumab-therapy-for-diabetic-macular-edema-based-on-real-life-data
#8
I Chatziralli, M Santarelli, N Patrao, L Nicholson, M Zola, R Rajendram, P Hykin, S Sivaprasad
PurposeTo determine the average time-point at which it is best to define 'sub-optimal response' after ranibizumab treatment for diabetic macular edema (DME) based on the data obtained from real-life clinical practice.MethodsIn this retrospective observational study, 322 consecutive treatment naïve eyes with DME were treated with three loading doses of intravitreal ranibizumab followed by re-treatment based on decision of the treating physician on a case-by-case basis. The demographic data, clinic-based visual acuity measurements and central subfield thickness (CST) assessed on spectral domain optical coherence tomography (OCT) were evaluated at baseline (month 0), 1, 2, 3, 6, and 12 months...
June 16, 2017: Eye
https://www.readbyqxmd.com/read/28622270/dexamethasone-intravitreal-implant-for-the-treatment-of-recalcitrant-macular-edema-after-rhegmatogenous-retinal-detachment-repair
#9
Aristomenis Thanos, Bozho Todorich, Yoshihiro Yonekawa, Thanos D Papakostas, Tahsin Khundkar, Dean Eliott, Ashvani B Dass, George A Williams, Antonio Capone, Lisa J Faia, Jeremy D Wolfe, Tarek S Hassan, Alan J Ruby
PURPOSE: To investigate the efficacy of the intravitreal dexamethasone implant as the treatment for recalcitrant macular edema after successful rhegmatogenous retinal detachment repair. METHODS: A retrospective review of the medical records was performed on 17 consecutive patients (17 eyes) with recalcitrant macular edema associated with rhegmatogenous retinal detachment repair who were treated with a single or multiple injections of an intravitreal dexamethasone 0...
June 15, 2017: Retina
https://www.readbyqxmd.com/read/28620704/ranibizumab-versus-dexamethasone-implant-for-central-retinal-vein-occlusion-the-ranidex-study
#10
Irini Chatziralli, George Theodossiadis, Stamatina A Kabanarou, Efstratios Parikakis, Tina Xirou, Panagiotis Mitropoulos, Panagiotis Theodossiadis
PURPOSE: To compare intravitreal ranibizumab and dexamethasone implant in patients with macular edema (ME) secondary to central retinal vein occlusion (CRVO). METHODS: Participants were 42 treatment naive patients with ME due to CRVO, who received either intravitreal 0.5 mg ranibizumab (n = 25) or intravitreal 0.7 mg dexamethasone implant (n = 17). The main outcomes included the mean change in best corrected visual acuity (BCVA) and central subfield thickness (CST) at month 12 compared to baseline in the two groups...
June 15, 2017: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/28616715/effects-of-intravitreal-injection-of-bevacizumab-with-or-without-anterior-chamber-paracentesis-on-intraocular-pressure-and-peripapillary-retinal-nerve-fiber-layer-thickness-a-prospective-study
#11
Masoud Soheilian, Saeed Karimi, Talieh Montahae, Homayoun Nikkhah, Seyed Aliasghar Mosavi
PURPOSE: To investigate the effects of intravitreal injection of bevacizumab (IVB) with or without anterior chamber paracentesis on intraocular pressure (IOP) and peripapillary retinal nerve fiber layer (PRNFL) thickness. METHODS: In this prospective randomized clinical trial, 90 eyes with center involving diabetic macular edema or wet type age-related macular degeneration (AMD) were randomly assigned to receive IVB either without (group A) or with (group B) anterior chamber paracentesis...
June 14, 2017: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/28613352/comparison-of-ranibizumab-and-bevacizumab-for-macular-edema-secondary-to-retinal-vein-occlusions-in-routine-clinical-practice
#12
Mehnaz Khan, Karen M Wai, Fabiana Q Silva, Sunil Srivastava, Justis P Ehlers, Aleksandra Rachitskaya, Amy Babiuch, Ryan Deasy, Peter K Kaiser, Andrew P Schachat, Alex Yuan, Rishi P Singh
BACKGROUND AND OBJECTIVE: To determine outcomes of intravitreal ranibizumab (IVR) (Lucentis; Genentech, South San Francisco, CA) versus bevacizumab (IVB) (Avastin; Genentech, South San Francisco, CA) for treatment of macular edema (ME) secondary to retinal vein occlusion (RVO) in routine clinical practice. PATIENTS AND METHODS: A retrospective study identified treatment-naïve patients with ME secondary to RVO where treatment with either IVB or IVR was initiated...
June 1, 2017: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/28613220/optical-coherence-tomography-baseline-predictors-for-initial-best-corrected-visual-acuity-response-to-intravitreal-anti-vascular-endothelial-growth-factor-treatment-in-eyes-with-diabetic-macular-edema-the-chartres-study
#13
Ana R Santos, Miguel  Costa, Christian Schwartz, Dalila Alves, João Figueira, Rufino Silva, Jose G Cunha-Vaz
PURPOSE: To identify baseline optical coherence tomography morphologic characteristics predicting the visual response to anti-vascular endothelial growth factor therapy in diabetic macular edema. METHODS: Sixty-seven patients with diabetic macular edema completed a prospective, observational study (NCT01947881-CHARTRES). All patients received monthly intravitreal injections of Lucentis for 3 months followed by PRN treatment and underwent best-corrected visual acuity measurements and spectral domain optical coherence tomography at Baseline, Months 1, 2, 3, and 6...
May 2, 2017: Retina
https://www.readbyqxmd.com/read/28613217/macular-edema-after-cataract-surgery-in-eyes-with-preoperative-retinal-vein-occlusion
#14
Han Joo Cho, Hyun Ji Hwang, Hyoung Seok Kim, Dong Won Lee, Chul Gu Kim, Byoung Yeop Kim, Jong Woo Kim
PURPOSE: To evaluate the incidence of pseudophakic macular edema (PME) in eyes with a history of retinal vein occlusion before cataract surgery and to identify any associated risk factors. METHODS: The records of 21,332 eyes that underwent cataract surgery were retrospectively reviewed. Eyes that had retinal vein occlusion preoperatively with no evidence of macular pathology on optical coherence tomography at the time of surgery and no macular edema treatment at least 6 months before surgery were included...
May 2, 2017: Retina
https://www.readbyqxmd.com/read/28611650/anterior-360%C3%A2-synechiolysis-in-a-case-of-late-iridocorneal-adhesions-after-25-g-vitrectomy-surgical-and-physiopathogenetic-aspects
#15
Raffaele Nuzzi, Francesca Monteu
We describe the case of an 86-year-old patient, pseudophakic in both eyes and with high myopia, who had previously had a 25-G vitrectomy with 20% C3F8 used as a tamponade due to a total retinal detachment with choroidal hemorrhages and macular hole. At the postoperative 4-month follow-up, we found 360° iridocorneal synechiae with elevated intraocular pressure due to angle closure in all sectors, with an adherent retina and in the absence of choroidal hemorrhage/detachment and of corneal edema or endothelial damage...
January 2017: Case Reports in Ophthalmology
https://www.readbyqxmd.com/read/28611649/a-case-of-diabetic-macular-edema-with-prominent-chorioretinal-folds
#16
Takaki Sato, Ryohsuke Kohmoto, Masanori Fukumoto, Seita Morishita, Daisaku Kimura, Kensuke Tajiri, Takatoshi Kobayashi, Teruyo Kida, Shota Kojima, Tsunehiko Ikeda
PURPOSE: To report a case of diabetic macular edema with prominent chorioretinal folds. CASE REPORT: This study involved a 55-year-old male with untreated bilateral diabetic retinopathy who had undergone cataract surgery at another clinic. Following that surgery, diabetic macular edema rapidly exacerbated, accentuating marked cystoid macular edema and radial chorioretinal folds in the macula. Investigation of his medical history revealed that in addition to diabetes, he had uncontrolled hypertension and severe diabetic nephropathy...
January 2017: Case Reports in Ophthalmology
https://www.readbyqxmd.com/read/28610573/correlation-between-short-and-long-term-effects-of-intravitreal-ranibizumab-therapy-on-macular-edema-after-branch-retinal-vein-occlusion-a-prospective-observational-study
#17
Yoshiro Minami, Taiji Nagaoka, Akihiro Ishibazawa, Akitoshi Yoshida
BACKGROUND: The correlation between the short- and long-term effects of intravitreal ranibizumab (IVR) on macular edema after branch retinal vein occlusion (BRVO) remains unclear. We assessed the correlation between the short- and long-term effects of IVR on macular edema after BRVO. METHODS: Twenty-one eyes with macular edema after BRVO were enrolled in this prospective observational study. We measured the foveal thickness (FT) and the best-corrected visual acuity (BCVA) before, 1 day after, and 1 month after IVR (0...
June 13, 2017: BMC Ophthalmology
https://www.readbyqxmd.com/read/28608031/adalimumab-in-refractory-cystoid-macular-edema-associated-with-birdshot-chorioretinopathy
#18
Laura R Steeples, Paul Spry, Richard W J Lee, Ester Carreño
PURPOSE: To report the clinical outcomes of adalimumab therapy in cases of birdshot chorioretinitis (BCR) with cystoid macular edema (CME) refractory to conventional immunotherapy. METHODS: This is a retrospective case series of three BCR patients treated with adalimumab for refractory CME. The main outcome measure was central subfield thickness (CST) on optical coherence tomography. Any patients treated with local steroids and/or receiving systemic steroids higher than 40 mg prednisolone daily during adalimumab therapy were excluded...
June 12, 2017: International Ophthalmology
https://www.readbyqxmd.com/read/28603408/efficacy-of-nepafenac-ophthalmic-suspension-0-1-in-improving-clinical-outcomes-following-cataract-surgery-in-patients-with-diabetes-an-analysis-of-two-randomized-studies
#19
Rishi P Singh, Giovanni Staurenghi, Ayala Pollack, Adeniyi Adewale, Thomas M Walker, Dana Sager, Robert Lehmann
OBJECTIVE: To assess the efficacy of nepafenac 0.1% ophthalmic suspension in improving the clinical outcomes following cataract surgery (CS) in patients with nonproliferative diabetic retinopathy. METHODS: In two similar multicenter, randomized studies, patients received either nepafenac 0.1% or vehicle, instilled three times daily starting a day prior to surgery and continuing for 90 days postoperatively. A post hoc analysis of these two studies was conducted to assess 1) the likelihood for development of postoperative macular edema (ME), based on the percentage of patients who developed ME (≥30% increase from preoperative baseline in central subfield macular thickness) within 90 days following CS and 2) best-corrected visual acuity (BCVA) endpoints, including the percentage of patients with a BCVA improvement of ≥15 letters from preoperative baseline to Day 14 and maintained through Day 90...
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/28602949/connexin-channel-and-its-role-in-diabetic-retinopathy
#20
REVIEW
Sayon Roy, Jean X Jiang, An-Fei Li, Dongjoon Kim
Diabetic retinopathy is the leading cause of blindness in the working age population. Unfortunately, there is no cure for this devastating ocular complication. The early stage of diabetic retinopathy is characterized by the loss of various cell types in the retina, namely endothelial cells and pericytes. As the disease progresses, vascular leakage, a clinical hallmark of diabetic retinopathy, becomes evident and may eventually lead to diabetic macular edema, the most common cause of vision loss in diabetic retinopathy...
June 7, 2017: Progress in Retinal and Eye Research
keyword
keyword
1766
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"